Molecular - Near Patient Testing

HiberGene Diagnostics, located in Dublin, Ireland, develop, manufacture and markets molecular diagnostic tests for human infectious diseases, using the LAMP (Loop Mediated Isothermal Amplification) technology - a technology can be employed in near patient care settings.

Their current portfolio of molecular diagnostic products for human infectious diseases, includes rapid and easy to use tests for Meningococcus, Group B Streptococcus, C. Difficile, Mycoplasma pneumoniae, Pneumococcus & Meningococcus and Influenza A & B. 

Unmet Clinical Need:

• Real-time, intrapartum testing method
• Rapid results – Current culture methods can take up to 72 hrs and are not viable for intrapartum screening
• Rapid test for newborns

The Hg Solution:

• Simple, intrapartum test with real-time results
• Positive results in < 60 minutes during labour
• Test for symptomatic newborns

The HG GBS test allows for antepartum GBS screening, intrapartum testing and testing for at risk or symptomatic new-borns to provide rapid and effective treatment of GBS.

Unmet Clinical Need:

• Accurate diagnosis
• Rapid results – Current culture methods can take up to 72 hrs
• Non-invasive samples

The Hg Solution:

• 100% Sensitivity and Specificity in extract samples
• Results in ≤ 60 minutes
• Compatible with throat swab samples

The HG Meningococcus test allows patients who test positive to be effectively and efficiently treated with target antibiotics.

It also allows MD to be rapidly ruled out with a negative result saving costs and time for the hospital and avoiding unnecessary antibiotics for the patients.

Unmet Clinical Need:

• Targeted test to diagnose bacterial meningitis – large panel tests are costly and give unwanted results
• Rapid results – conventional culture methods can take to up 72 hours and are not viable for such an aggressive infection
• Differential diagnosis to inform clinical decisions

The Hg Solution:

• Targeted test to detect the two leading causes of bacterial meningitis
• Results in ≤ 60 minutes – enables timely isolation precautions and treatment
• Target-specific fluorescent detection provides differential diagnosis